Breaking News Instant updates and real-time market news.

BHC

Bausch Health

$20.50

-0.12 (-0.58%)

10:25
10/14/19
10/14
10:25
10/14/19
10:25

Bausch Health call volume above normal and directionally bullish

Bullish option flow detected in Bausch Health with 7,047 calls trading, 2x expected, and implied vol increasing almost 4 points to 53.17%. Nov-19 23 calls and Oct-19 20 puts are the most active options, with total volume in those strikes near 2,000 contracts. The Put/Call Ratio is 0.23. Earnings are expected on November 4th.

  • 04

    Nov

BHC Bausch Health
$20.50

-0.12 (-0.58%)

09/11/19
GUGG
09/11/19
INITIATION
Target $30
GUGG
Buy
Bausch Health initiated with a Buy at Guggenheim
Guggenheim analyst Dana Flanders started Bausch Health with a Buy rating and $30 price target.
09/11/19
GUGG
09/11/19
INITIATION
GUGG
Buy
Bausch Health initiated with a Buy at Guggenheim
Guggenheim analyst Dana Flanders initiated Bausch Health with a Buy rating and a $30 price target, citing the company's strong execution and the durability of its businessses. Flanders believes Bausch will lower its $27B in debt over the next few years, which "should translate to a double-digit compounded equity return for shareholders."
09/17/19
WELS
09/17/19
NO CHANGE
WELS
Underperform
Wells says two of Bausch's 'Significant Seven' not on UnitedHealth benefit list
Wells Fargo analyst David Maris noted that United Healthcare (UNH) released its Pharmacy Benefit Coverage update, which shows that as of January 2020 it is excluding Bausch Health's (BHC) Bryhali, which he said is one of the company's "Significant Seven" focus products. Another of the Significant Seven, Siliq, will no longer be covered under UnitedHealth's pharmacy benefit plans, said Maris. Two other Significant Seven members - Vyzulta and Relistor - are listed as required step therapy and needing a prior authorization, respectively, Maris added. The analyst, who thinks Bausch Health's pipeline and recently approved products are "unimpressive," keeps an Underperform rating on the stock. Reference Link
10/03/19
PIPR
10/03/19
NO CHANGE
Target $29
PIPR
Overweight
Bausch unlikely to face generic Xifaxan before 2028, says Piper Jaffray
Piper Jaffray analyst David Amsellem says he would not be worried that a generic Xifaxan entrant will emerge prior to the January 2028 launch date outlined in Bausch Health Companies' (BHC) settlement with Teva (TEVA) on its generic filing. The analyst highlights the "relatively complex nature" of Xifaxan and Bausch's "fairly deep intellectual property estate." As such, he continues to believe that visibility into a "durable" EBITDA for Bausch Health is high, with a longer-term annual growth "reaching at least the high single digits." He reiterates an Overweight rating on the shares with a $29 price target.

TODAY'S FREE FLY STORIES

HALO

Halozyme

$16.76

0.17 (1.02%)

16:12
11/12/19
11/12
16:12
11/12/19
16:12
Hot Stocks
Halozyme to offer $400M in convertible senior notes due 22024 »

Halozyme Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

TVTY

Tivity Health

$18.41

-0.005 (-0.03%)

16:12
11/12/19
11/12
16:12
11/12/19
16:12
Earnings
Tivity Health backs FY19 adjusted EPS $2.14-$2.32, consensus $2.21 »

Backs FY19 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

  • 10

    Dec

CDXC

ChromaDex

$2.84

-0.005 (-0.18%)

16:12
11/12/19
11/12
16:12
11/12/19
16:12
Earnings
ChromaDex reports Q3 EPS (12c), consensus (12c) »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

CBPX

Continental Building

$34.88

2.85 (8.90%)

16:12
11/12/19
11/12
16:12
11/12/19
16:12
Earnings
Continental Building reports Q3 EPS 39c, consensus 41c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

  • 13

    Nov

TRXC

TransEnterix

$0.31

0.0394 (14.80%)

16:12
11/12/19
11/12
16:12
11/12/19
16:12
Earnings
TransEnterix reports Q3 EPS (43c), consensus (8c) »

Reports Q3 revenue $2.0M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

HALO

Halozyme

$16.78

0.19 (1.15%)

16:12
11/12/19
11/12
16:12
11/12/19
16:12
Syndicate
Breaking Syndicate news story on Halozyme »

Halozyme files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

TVTY

Tivity Health

$18.42

0.005 (0.03%)

16:11
11/12/19
11/12
16:11
11/12/19
16:11
Earnings
Tivity Health reports Q3 adjusted EPS 46c, consensus 56c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

  • 10

    Dec

I

Intelsat

$20.80

-2.435 (-10.48%)

16:11
11/12/19
11/12
16:11
11/12/19
16:11
Downgrade
Intelsat rating change  »

Intelsat downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

TH

Target Hospitality

$5.03

-0.23 (-4.37%)

16:11
11/12/19
11/12
16:11
11/12/19
16:11
Earnings
Target Hospitality cuts FY19 revenue view to $318M-$328M from $340M-$350M »

Consensus $340.38M.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

  • 18

    Nov

MTSI

Macom

$24.38

0.93 (3.97%)

16:11
11/12/19
11/12
16:11
11/12/19
16:11
Earnings
Macom sees Q1 adj. EPS 1c-5c, consensus 1c »

Sees Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

  • 09

    Dec

RUN

Sunrun

$14.44

0.03 (0.21%)

16:11
11/12/19
11/12
16:11
11/12/19
16:11
Hot Stocks
Sunrun board authorizes $50M stock repurchase program »

The company announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

  • 04

    Dec

NBRV

Nabriva Therapeutics

$1.96

-0.03 (-1.51%)

16:11
11/12/19
11/12
16:11
11/12/19
16:11
Earnings
Nabriva Therapeutics reports Q3 EPS (90c), consensus (28c) »

Reports Q3 revenue $461K,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

CRNX

Crinetics

$19.16

-0.34 (-1.74%)

16:11
11/12/19
11/12
16:11
11/12/19
16:11
Earnings
Crinetics reports Q3 EPS (60c), consensus (57c) »

Reports Q3 revenue $505K,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VRAY

ViewRay

$2.48

-0.14 (-5.34%)

16:11
11/12/19
11/12
16:11
11/12/19
16:11
Earnings
ViewRay reaffirms FY19 revenue view $80M-$95M, consensus $89.28M »

Sees FY19 total cash…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

RUN

Sunrun

$14.48

0.065 (0.45%)

16:11
11/12/19
11/12
16:11
11/12/19
16:11
Hot Stocks
Breaking Hot Stocks news story on Sunrun »

Sunrun sees Q4…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

  • 04

    Dec

TH

Target Hospitality

$4.99

-0.27 (-5.13%)

16:10
11/12/19
11/12
16:10
11/12/19
16:10
Earnings
Target Hospitality reports Q3 adjusted EPS 11c, consensus 15c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

  • 18

    Nov

RUN

Sunrun

$14.44

0.03 (0.21%)

16:10
11/12/19
11/12
16:10
11/12/19
16:10
Earnings
Sunrun reports Q3 EPS 23c, consensus 15c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

  • 04

    Dec

VRAY

ViewRay

$2.48

-0.145 (-5.53%)

16:10
11/12/19
11/12
16:10
11/12/19
16:10
Earnings
ViewRay reports Q3 EPS (21c), consensus (27c) »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

MTSI

Macom

$24.22

0.77 (3.28%)

16:10
11/12/19
11/12
16:10
11/12/19
16:10
Earnings
Macom reports Q4 adj. EPS 1c, consensus (2c) »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

  • 09

    Dec

MYO

Myomo

$0.65

-0.051 (-7.25%)

16:09
11/12/19
11/12
16:09
11/12/19
16:09
Earnings
Myomo reports Q3 EPS (16c), consensus (16c) »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

BDSI

BioDelivery Sciences

$5.84

(0.00%)

16:09
11/12/19
11/12
16:09
11/12/19
16:09
Earnings
BioDelivery Sciences raises FY19 revenue view to $105M-$110M from $101M - $105M »

Consensus for FY19…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

  • 17

    Dec

MYO

Myomo

$0.65

-0.051 (-7.25%)

16:09
11/12/19
11/12
16:09
11/12/19
16:09
Earnings
Myomo reports Q3 EPS (16c), consensus (16c) »

Myomo reports Q3 EPS…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

AGTC

Applied Genetic

$3.15

-0.005 (-0.16%)

16:09
11/12/19
11/12
16:09
11/12/19
16:09
Earnings
Applied Genetic reports Q3 EPS (64c), consensus (60c) »

As of September 30, 2019,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

  • 19

    Nov

  • 04

    Dec

CLPR

Clipper Realty

$9.76

-0.18 (-1.81%)

16:09
11/12/19
11/12
16:09
11/12/19
16:09
Earnings
Clipper Realty reports Q3 adjusted FFO 12, consensus 12c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

MRKR

Marker Therapeutics

$3.91

-0.08 (-2.01%)

16:08
11/12/19
11/12
16:08
11/12/19
16:08
Earnings
Marker Therapeutics reports Q3 EPS (12c), consensus (13c) »

At September 30 Marker…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.